These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25548841)

  • 1. Patient satisfaction and safety with aesthetic onabotulinumtoxinA after at least 5 years: a retrospective cross-sectional analysis of 4,402 glabellar treatments.
    Trindade de Almeida A; Carruthers J; Cox SE; Goldman MP; Wheeler S; Gallagher CJ
    Dermatol Surg; 2015 Jan; 41 Suppl 1():S19-28. PubMed ID: 25548841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment.
    Carruthers A; Sadick N; Brandt F; Trindade de Almeida AR; Fagien S; Goodman GJ; Raspaldo H; Smith K; Darmody S; Gallagher CJ; Street J; Romagnano L
    Dermatol Surg; 2015 Jun; 41(6):693-701. PubMed ID: 25973559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.
    Rivers JK; Bertucci V; McGillivray W; Muhn C; Rosen N; Solish N; Weichman BM; Wheeler S; Daniels SR; Gallagher CJ
    Dermatol Surg; 2015 Aug; 41(8):950-9. PubMed ID: 26218728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of OnabotulinumtoxinA treatment for crow's feet lines on patient-reported outcomes.
    Dayan S; Coleman WP; Dover JS; De Boulle K; Street J; Romagnano L; Daniels S; Kowalski JW; Lei X; Lee E
    Dermatol Surg; 2015 Jan; 41 Suppl 1():S67-74. PubMed ID: 25548848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin: examining duration of effect in facial aesthetic applications.
    Flynn TC
    Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forehead Line Treatment With OnabotulinumtoxinA in Subjects With Forehead and Glabellar Facial Rhytids: A Phase 3 Study.
    Fagien S; Cohen JL; Coleman W; Monheit G; Carruthers J; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
    Dermatol Surg; 2017 Dec; 43 Suppl 3():S274-S284. PubMed ID: 33065953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of total joint arthroplasty and joint preserving surgery in younger patients evaluated by alternative outcome measures.
    Klit J
    Dan Med J; 2014 Apr; 61(4):B4836. PubMed ID: 24814600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
    Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
    Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of onabotulinumtoxinA in the treatment of upper facial lines from global registration studies in 5298 participants: A meta-analysis.
    Brin MF; De Boulle K; Liew S; Carruthers A; Carruthers J; Rivkin A; Wu Y; Kawashima M; Yushmanova I; Boodhoo TI; Lee E
    JAAD Int; 2024 Mar; 14():4-18. PubMed ID: 38035126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines.
    Cohen JL; Dayan SH; Cox SE; Yalamanchili R; Tardie G
    Dermatol Surg; 2012 Sep; 38(9):1497-505. PubMed ID: 22621180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A two-phase, retrospective analysis evaluating efficacy of and patient satisfaction with abobotulinumtoxina used to treat dynamic facial rhytides.
    Kiripolsky MG; Peterson JD; Guiha I; Goldman MP
    Dermatol Surg; 2011 Oct; 37(10):1443-7. PubMed ID: 21649790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W; Rappl T
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines.
    Glogau R; Kane M; Beddingfield F; Somogyi C; Lei X; Caulkins C; Gallagher C
    Dermatol Surg; 2012 Nov; 38(11):1794-803. PubMed ID: 23106853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines.
    Beer KR; Boyd C; Patel RK; Bowen B; James SP; Brin MF
    J Drugs Dermatol; 2011 Jan; 10(1):39-44. PubMed ID: 21197522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial.
    Carruthers A; Bruce S; de Coninck A; Connolly S; Cox SE; Davis PG; Campo A; Lei X; Somogyi C; Lee E; McLean H; Beddingfield F
    Dermatol Surg; 2014 Nov; 40(11):1181-90. PubMed ID: 25347451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis.
    Yoelin SG; Fagien S; Cox SE; Davis PG; Campo A; Caulkins CA; Gallagher CJ
    Dermatol Surg; 2014 Oct; 40(10):1118-24. PubMed ID: 25229783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis.
    Kennelly M; Dmochowski R; Ethans K; Karsenty G; Schulte-Baukloh H; Jenkins B; Thompson C; Li D; Haag-Molkenteller C
    Urology; 2013 Mar; 81(3):491-7. PubMed ID: 23290144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.